| 12.04 0.53 (4.6%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.56 |
1-year : | 17.01 |
| Resists | First : | 12.47 |
Second : | 14.56 |
| Pivot price | 10.86 |
|||
| Supports | First : | 11.06 |
Second : | 10.19 |
| MAs | MA(5) : | 11.25 |
MA(20) : | 10.95 |
| MA(100) : | 8.84 |
MA(250) : | 7.4 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 79 |
D(3) : | 63.9 |
| RSI | RSI(14): 64.6 |
|||
| 52-week | High : | 15.34 | Low : | 4.09 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ENTA ] has closed Bollinger Bands are 36.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.48 - 12.53 | 12.53 - 12.58 |
| Low: | 10.98 - 11.04 | 11.04 - 11.09 |
| Close: | 11.95 - 12.04 | 12.04 - 12.12 |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Tue, 04 Nov 2025
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
Tue, 04 Nov 2025
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has caught the attention of institutional investors who hold a sizeable 44% stake - Yahoo Finance
Thu, 30 Oct 2025
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 30% - Sahm
Thu, 02 Oct 2025
Enanta pharmaceuticals prices $65M common stock offering - MSN
Thu, 02 Oct 2025
Enanta Pharmaceuticals raises $74.75 million in public offering - Investing.com
Tue, 30 Sep 2025
Enanta Pharmaceuticals falls on public offering of common stock - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 29 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 5 (%) |
| Held by Institutions | 71.4 (%) |
| Shares Short | 2,810 (K) |
| Shares Short P.Month | 2,850 (K) |
| EPS | -4.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.71 |
| Profit Margin | -142 % |
| Operating Margin | -103.2 % |
| Return on Assets (ttm) | -17.3 % |
| Return on Equity (ttm) | -80.7 % |
| Qtrly Rev. Growth | 1.8 % |
| Gross Profit (p.s.) | 2.24 |
| Sales Per Share | 2.24 |
| EBITDA (p.s.) | -3.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -2.79 |
| PEG Ratio | 0 |
| Price to Book value | 3.24 |
| Price to Sales | 5.35 |
| Price to Cash Flow | -14.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|